Last updated: February 27, 2026
What is the drug associated with NDC: 00093-7272?
The National Drug Code (NDC) 00093-7272 corresponds to Zanubrutinib (Brukinsa), a Bruton tyrosine kinase (BTK) inhibitor approved by the FDA for the treatment of certain B-cell malignancies, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). It is a targeted therapy marketed by BeiGene.
What is the market size for Zanubrutinib?
The global B-cell malignancies market was valued at approximately USD 8.2 billion in 2022, with targeted therapies accounting for roughly 40% of this market. The adoption of BTK inhibitors, including Ibrutinib and Acalabrutinib, has increased significantly since their approvals in early 2010s.
Market segments
| Segment |
2022 Market Share |
Key Drugs |
Notes |
| Chronic Lymphocytic Leukemia (CLL) |
45% |
Ibrutinib (Imbruvica), Acalabrutinib (Calquence), Zanubrutinib (Brukinsa) |
Dominates first-line treatment |
| Mantle Cell Lymphoma (MCL) |
35% |
Ibrutinib, Zanubrutinib |
Second-line, relapsed/refractory |
| Other B-cell cancers |
20% |
Various |
Marginal zone lymphoma, Waldenström macroglobulinemia |
Forecasts indicate a compound annual growth rate (CAGR) of around 8% for this segment over the next five years driven by increased adoption of BTK inhibitors in first- and second-line settings.
What factors influence Zanubrutinib's pricing?
Competitive landscape
- Ibrutinib (marketed as Imbruvica) has a market dominance with peak sales over USD 6 billion before biosimilar entry.
- Acalabrutinib (Calquence) achieved USD 1.2 billion in sales in 2022.
- Zanubrutinib entered the market in 2019 and has gained approval for multiple indications, rapidly expanding its use.
Regulatory and reimbursement factors
- Pricing is influenced by payer negotiations, formulary inclusion, and regional approvals.
- The drug's pricing has been adjusted to compete with established BTK inhibitors.
Manufacturing and R&D costs
- Brukinsa's manufacturing costs are comparable to other small-molecule cancer therapies, averaging around USD 1,200 per treatment course.
- R&D investments exceed USD 500 million for its development and clinical trials.
What are the current pricing benchmarks?
| Region |
Approximate Wholesale Price per 30-day supply |
Notes |
| US |
USD 13,500 |
Available through major payers, with negotiated discounts |
| Europe |
EUR 11,000 |
Varies by country and reimbursement scheme |
| China |
CNY 80,000 (~USD 11,000) |
Pricing lower due to regional pricing policies |
Pricing strategies for new indications and regional markets vary, with US prices generally higher than elsewhere.
What are the price projection trends?
Short-term projections (2023–2025)
- Price stabilization: US wholesale prices are expected to stay within USD 13,000–USD 14,000 per month due to market competition.
- Discounting: Payer discounts and patient assistance programs will reduce net prices by 20–30%.
- Reimbursement expansion: Increased formulary inclusion will expand access but exert downward pressure on list prices.
Long-term projections (2026–2030)
- Pricing pressure: Entry of biosimilars or generic BTK inhibitors in the US could lower prices by 15–25%.
- Market growth: As indications expand and usage increases, total revenues may grow despite price erosion.
- International markets: Steady price declines expected in Europe and China due to price regulation and generic competition.
Key drivers influencing price trajectory
- Competition from biosimilars and generics.
- Payer negotiation strength.
- Clinical advancements extending the drug's indication spectrum.
- Regional reimbursement policies.
What is the revenue outlook?
Estimated global sales are projected to reach USD 2.0–2.5 billion by 2030, driven primarily by China, the US, and Europe. These figures depend on market penetration, competition, and regulatory developments.
Conclusion
Zanubrutinib (NDC: 00093-7272) is positioned as a competitive BTK inhibitor with expanding indications. Pricing remains aligned with that of other branded BTK inhibitors, with stabilization expected short-term and moderate declines over the longer term due to biosimilar competition. Revenue growth will depend on market uptake, approval of new indications, and regional pricing dynamics.
Key Takeaways
- Zanubrutinib entered a competitive market dominated by Ibrutinib and Acalabrutinib.
- US wholesale prices hover around USD 13,500 per month, with similar prices in Europe and China.
- Market growth forecasts indicate a CAGR of approximately 8%, with sales reaching USD 2.5 billion by 2030.
- Prices are likely to stabilize short-term, then decline as biosimilars and generics enter regional markets.
- Reimbursement policies and clinical trial developments will significantly influence future pricing and sales.
FAQs
1. How does Zanubrutinib's price compare to Ibrutinib?
Zanubrutinib's US wholesale price is generally similar but slightly lower than Ibrutinib, driven by competition and formulary negotiations.
2. Are there regional price differences for Zanubrutinib?
Yes. US prices are higher compared to Europe and China due to different reimbursement systems, regulations, and negotiated discounts.
3. How will biosimilar entries affect Zanubrutinib prices?
Biosimilars and generics may lead to price reductions of 15–25% over the next 5 years, especially in regions with strict price regulation.
4. What are major factors influencing Zanubrutinib's market growth?
Indication expansion, clinical trial results improving outcomes, payer coverage, and regional approvals drive growth.
5. Is Zanubrutinib likely to gain more indications?
Yes. Ongoing trials in additional hematologic cancers could expand its market and influence pricing strategies.
References
[1] GlobalData. (2022). Hematologic malignancies market report.
[2] IQVIA. (2022). US Oncology Market Trends Report.
[3] FDA. (2020). Zanubrutinib approval announcement.
[4] BeiGene. (2023). Brukinsa prescribing information.
[5] WHO. (2023). Global cancer statistics.
